Strict medication adherence, which reflects the process by which patients take their medication as prescribed, is crucial for the use of direct oral anticoagulants (DOACs). Therefore, technological devices may serve as promising tools for assessing adherence. We aimed to systematically review the literature focusing on electronically monitored adherence (EMA) to DOACs. All studies indexed in EMBASE, Cochrane Library, MEDLINE, Scopus, and Web of Science from inception until September 1, 2023, were searched. Original studies targeting the query topics were included, findings were categorized and narratively synthetized. Adherence data, including the quality of data reporting bias, were evaluated using the EMERGE guideline. The review protocol was registered in the PROSPERO database (ID CRD42023441161). Out of the 5911 potential hits, 19 articles, comprising 15 research studies, were identified. These studies enrolled 4163 patients (median 72.1 years; 57.9% males), usually chronically treated with DOACs for atrial fibrillation. EMA was measured in 3451 patients by seven different devices from eight manufacturers; the median population tracked with electronic monitoring was 56 patients over 5 months per study. Observational studies resulted in 88.6% and interventional studies resulted in 92.5% of EMA to DOACs, mostly monitoring regimen and taking adherence. Two studies reported high-quality adherence data, whereas 11 reported low-quality adherence data. The item described in the EMERGE guideline as affecting adherence by measurement method, as appropriate, has rarely been addressed. This review broadens the understanding of the overall high EMA to DOACs reported across various study populations and designs. Furthermore, due to the identified gaps in current literature, it highlights the pressing need for standardized methodologies and improved adherence reporting. This study was supported by the GAUK 328322 and SVV 220665.

Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Steffel J, Collins R, Antz M, et al. European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676. doi:10.1093/europace/euab065 PubMed DOI PMC

Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.x PubMed DOI PMC

Sikorska J, Uprichard J. Direct oral anticoagulants: a quick guide. Eur Cardiol. 2017;12(1):40–45. doi:10.15420/ecr.2017:11:2 PubMed DOI PMC

Mason M, Cho Y, Rayo J, Gong Y, Harris M, Jiang Y. Technologies for medication adherence monitoring and technology assessment criteria: narrative review. JMIR mHealth uHealth. 2022;10(3):e35157. doi:10.2196/35157 PubMed DOI PMC

Boehme P, Wienand P, Herrmann M, Truebel H, Mondritzki T. New digital adherence devices could prevent millions of strokes from atrial fibrillation by the end of the next century. Med Hypotheses. 2017;108:46–50. doi:10.1016/j.mehy.2017.07.034 PubMed DOI

Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world- a problem or a myth? Semin Thromb Hemost. 2014;40(8):852–859. doi:10.1055/s-0034-1395156 PubMed DOI

Turakhia MP, Kaiser DW. Transforming the care of atrial fibrillation with mobile health. J Interv Card Electrophysiol. 2016;47(1):45–50. doi:10.1007/s10840-016-0136-3 PubMed DOI PMC

Kopecky S. New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. Am J Cardiovasc Drugs. 2012;12(5):287–294. doi:10.1007/BF03261837 PubMed DOI

Pouls BPH, Vriezekolk JE, Bekker CL, et al. Effect of interactive eHealth interventions on improving medication adherence in adults with long-term medication: systematic review. J Med Internet Res. 2021;23(1):e18901. doi:10.2196/18901 PubMed DOI PMC

Maly J, Dvorackova S, Zimcikova E, et al. Patterns in anticoagulant utilization in the Czech Republic during 2007–2017. J Thromb Thrombolysis. 2019;47(2):305–311. doi:10.1007/s11239-019-01806-z PubMed DOI

an Heuckelum M, van den Ende CHM, Houterman AEJ, Heemskerk CPM, van Dulmen S, van den Bemt BJF. The effect of electronic monitoring feedback on medication adherence and clinical outcomes: a systematic review. PLoS One. 2017;12(10):e0185453. doi:10.1371/journal.pone.0185453 PubMed DOI PMC

Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969 PubMed DOI

Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–523. doi:10.1093/europace/euu311 PubMed DOI

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PubMed PMC

De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med. 2018;169(1):30–35. doi:10.7326/M18-0543 PubMed DOI PMC

Dvořáčková S, Ládová K, Malý J, Kolář J, Penka M. Adherence k léčbě non-vitamin K perorálními antikoagulancii u nevalvulární fibrilace síní: přehled literatury [Medication adherence to non-vitamin K antagonist oral anticoagulants at non-valvular atrial fibrillation - the literature review]. Vnitr Lek. 2017;63(10):633–639. doi:10.36290/vnl.2017.125 PubMed DOI

Grymonprez M, Steurbaut S, Capiau A, et al. Minimal adherence threshold to non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death: a nationwide cohort study. Cardiovasc Drugs Ther. 2025;39(1):107–17. PubMed

Kim D, Yang PS, Jang E, et al. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Europace. 2020;22(4):547–557. doi:10.1093/europace/euz273 PubMed DOI

Ruff C, Koukalova L, Haefeli WE, Meid AD. The role of adherence thresholds for development and performance aspects of a prediction model for direct oral anticoagulation adherence. Front Pharmacol. 2019;10:113. doi:10.3389/fphar.2019.00113 PubMed DOI PMC

Solla-Ruiz I, Villanueva-Benito I, Paredes-Galán E, et al. Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study. Thromb Res. 2019;179:20–27. doi:10.1016/j.thromres.2019.04.023 PubMed DOI

Turakhia M, Sundaram V, Smith SN, et al. Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. Am Heart J. 2021;237:68–78. doi:10.1016/j.ahj.2021.02.023 PubMed DOI

Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015;313(14):1443–1450. doi:10.1001/jama.2015.2761 PubMed DOI

Polymeris AA, Albert V, Hersberger KE, et al. Protocol for MAAESTRO: electronic monitoring and improvement of adherence to direct oral anticoagulant treatment-a randomized crossover study of an educational and reminder-based intervention in ischemic stroke patients under polypharmacy. Front Neurol. 2018;9:1134. doi:10.3389/fneur.2018.01134 PubMed DOI PMC

Hagiwara N, Shigha T. Surveys on Medication Adherence of Anticoagulant Drugs and Investigation for Improvement of Medication Adherence by Educational Program in Non-Valvular Atrial Fibrillation Patients. WHO, International Clinical Trials Registry Platform 2018;JPRN-UMIN000031132. Available from: https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000031132. Accessed June 5, 2024.

Márquez-Contreras E, Martell-Carlos N, Gil-Guillén V, et al. Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study. Curr Med Res Opin. 2016;32(12):2013–2020. doi:10.1080/03007995.2016.1227311 PubMed DOI

Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, et al. Quality of life with rivaroxaban in patients with non-valvular atrial fibrillation by therapeutic compliance. Qual Life Res. 2017;26(3):647–654. doi:10.1007/s11136-016-1489-x PubMed DOI

Shiga T, Kimura T, Fukushima N, et al. Electronic monitoring of adherence to once-daily and twice-daily direct oral anticoagulants in patients with atrial fibrillation: baseline data from the SMAAP-AF trial. J Arrhythm. 2021;37(3):616–625. doi:10.1002/joa3.12532 PubMed DOI PMC

Shiga T, Kimura T, Fukushima N, et al. Effects of a pharmacist-led educational interventional program on electronic monitoring-assessed adherence to direct oral anticoagulants: a randomized, controlled trial in patients with nonvalvular atrial fibrillation. Clin Ther. 2022;44(11):1494–1505. doi:10.1016/j.clinthera.2022.09.011 PubMed DOI

Desteghe L, Kluts K, Vijgen J, et al. The health buddies app as a novel tool to improve adherence and knowledge in atrial fibrillation patients: a pilot study. JMIR mHealth uHealth. 2017;5(7):e98. doi:10.2196/mhealth.7420 PubMed DOI PMC

Márquez-Contreras E, Martell-Claros N, Márquez-Rivero S, et al. Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study). Curr Med Res Opin. 2018;34(7):1301–1308. doi:10.1080/03007995.2018.1435519 PubMed DOI

Desteghe L, Vijgen J, Koopman P, et al. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1394–1403. doi:10.1093/eurheartj/ehx762 PubMed DOI

Desteghe L, Engelhard L, Vijgen J, et al. Effect of reinforced, targeted in-person education using the Jessa Atrial fibrillation knowledge questionnaire in patients with atrial fibrillation: a randomized controlled trial. Eur J Cardiovasc Nurs. 2019;18(3):194–203. doi:10.1177/1474515118804353 PubMed DOI

Montalescot G, Brotons C, Cosyns B, et al. Educational impact on apixaban adherence in atrial fibrillation (the AEGEAN STUDY): a randomized clinical trial. Am J Cardiovasc Drugs. 2020;20(1):61–71. doi:10.1007/s40256-019-00356-2 PubMed DOI PMC

Toscos T, Drouin M, Pater JA, et al. Medication adherence for atrial fibrillation patients: triangulating measures from a smart pill bottle, e-prescribing software, and patient communication through the electronic health record. JAMIA Open. 2020;3(2):233–242. doi:10.1093/jamiaopen/ooaa007 PubMed DOI PMC

Toscos T, Coupe A, Wagner S, et al. Engaging patients in atrial fibrillation management via digital health technology: the impact of tailored messaging. J Innov Card Rhythm Manag. 2020;11(8):4209–4217. doi:10.19102/icrm.2020.110802 PubMed DOI PMC

Knaepen L, Delesie M, Vijgen J, et al. Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population. Clin Res Cardiol. 2023;112(12):1812–1823. doi:10.1007/s00392-023-02261-w PubMed DOI PMC

Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. Stroke. 2017;48(5):1416–1419. doi:10.1161/STROKEAHA.116.016281 PubMed DOI PMC

Albert V, Polymeris AA, Dietrich F, et al. Insights into direct oral anticoagulant therapy implementation of stroke survivors with atrial fibrillation in an ambulatory setting. J Stroke Cerebrovasc Dis. 2021;30(2):105530. doi:10.1016/j.jstrokecerebrovasdis.2020.105530 PubMed DOI

Dietrich F, Polymeris AA, Verbeek M, et al. Impact of the COVID-19 lockdown on the adherence of stroke patients to direct oral anticoagulants: a secondary analysis from the MAAESTRO study. J Neurol. 2022;269(1):19–25. doi:10.1007/s00415-021-10631-5 PubMed DOI PMC

Albert V, Baumgartner PC, Hersberger KE, Arnet I. How do elderly outpatients manage polypharmacy including DOAC - A qualitative analysis highlighting a need for counselling. Res Social Adm Pharm. 2022;18(6):3019–3026. doi:10.1016/j.sapharm.2021.07.027 PubMed DOI

Dotta-Celio J, Alatri A, Locatelli I, et al. Patient adherence to rivaroxaban in deep vein thrombosis, a cohort study in Switzerland: quantitative results. Int J Clin Pharm. 2019;41(6):1625–1633. doi:10.1007/s11096-019-00928-x PubMed DOI

Lebel B, Malherbe M, Gouzy S, et al. Oral thromboprophylaxis following total Hip replacement: the issue of compliance. Orthop Traumatol Surg Res. 2012;98(2):186–192. doi:10.1016/j.otsr.2011.10.010 PubMed DOI

Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26(12):1437–1441. doi:10.1002/pds.4334 PubMed DOI

Cook P, Schmiege S, McClean M, Aagaard L, Kahook M. Practical and analytic issues in the electronic assessment of adherence. West J Nurs Res. 2012;34(5):598–620. doi:10.1177/0193945911427153 PubMed DOI

Insel KC, Einstein GO, Morrow DG, Koerner KM, Hepworth JT. Multifaceted prospective memory intervention to improve medication adherence. J Am Geriatr Soc. 2016;64(3):561–568. doi:10.1111/jgs.14032 PubMed DOI PMC

Kessler JB, Troxel AB, Asch DA, et al. Partners and alerts in medication adherence: a randomized clinical trial. J Gen Intern Med. 2018;33(9):1536–1542. doi:10.1007/s11606-018-4389-7 PubMed DOI PMC

Vervloet M, van Dijk L, de Bakker DH, et al. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial. Diabet Med. 2014;31(7):821–828. doi:10.1111/dme.12439 PubMed DOI

Piersma-Wichers M, Elling T, de Vries-Bots AMB, Kooistra HAM, Meijer K. Convenience and satisfaction in direct oral anticoagulant-treated patients with atrial fibrillation. Res Pract Thromb Haemost. 2021;5(6):e12577. doi:10.1002/rth2.12577 PubMed DOI PMC

Tran MH, Nguyen HH, Mai QK, Pham HT. Knowledge and medication adherence of oral anticoagulant-taking patients in Vietnam. Res Pract Thromb Haemost. 2023;7(1):100044. doi:10.1016/j.rpth.2023.100044 PubMed DOI PMC

Toorop MMA, van Rein N, Nierman MC, et al. Self-reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants. Res Pract Thromb Haemost. 2020;4(4):586–593. doi:10.1002/rth2.12316 PubMed DOI PMC

Speed V, Auyeung V, Patel JP, et al. Adherence to rivaroxaban for the treatment of venous thromboembolism-results from the FIRST registry. Res Pract Thromb Haemost. 2021;5(8):e12614. doi:10.1002/rth2.12614 PubMed DOI PMC

World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.

Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. doi:10.3389/fphar.2013.00091 PubMed DOI PMC

Weingarten MA, Cannon BS. Age as a major factor affecting adherence to medication for hypertension in a general practice population. Fam Pract. 1988;5(4):294–296. doi:10.1093/fampra/5.4.294 PubMed DOI

Davis DP, Jandrisevits MD, Iles S, Weber TR, Gallo LC. Demographic, socioeconomic, and psychological factors related to medication non-adherence among emergency department patients. J Emerg Med. 2012;43(5):773–785. doi:10.1016/j.jemermed.2009.04.008 PubMed DOI

Leslie KH, McCowan C, Pell JP. Adherence to cardiovascular medication: a review of systematic reviews. J Public Health. 2019;41(1):e84–94. doi:10.1093/pubmed/fdy088 PubMed DOI PMC

Komen JJ, Pottegård A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722–1730. doi:10.1093/europace/euab091 PubMed DOI PMC

Sabaté M, Vidal X, Ballarin E, et al. Adherence to direct oral anticoagulants in patients with non-valvular atrial fibrillation: a cross-national comparison in six European countries (2008–2015). Front Pharmacol. 2021;12:682890. doi:10.3389/fphar.2021.682890 PubMed DOI PMC

Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236. doi:10.1186/s12872-017-0671-6 PubMed DOI PMC

Coleman CI, Tangirala M, Evers T. Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol. 2016;212:171–173. doi:10.1016/j.ijcard.2016.03.051 PubMed DOI

Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2016;22(11):1319–1329. doi:10.18553/jmcp.2016.22.11.1319 PubMed DOI PMC

Wirbka L, Haefeli WE, Meid AD. Estimated thresholds of minimum necessary adherence for effective treatment with direct oral anticoagulants - A retrospective cohort study in health insurance claims data. Patient Prefer Adherence. 2021;15:2209–2220. doi:10.2147/PPA.S324315 PubMed DOI PMC

McGrady ME, Ramsey RR. Using electronic monitoring devices to assess medication adherence: a research methods framework. J Gen Intern Med. 2020;35(9):2707–2714. doi:10.1007/s11606-020-05905-z PubMed DOI PMC

Dima AL, Allemann SS, Dunbar-Jacob J, Hughes DA, Vrijens B, Wilson IB. TEOS: a framework for constructing operational definitions of medication adherence based on timelines-events-objectives-sources. Br J Clin Pharmacol. 2021;87(6):2521–2533. doi:10.1111/bcp.14659 PubMed DOI

Sinnappah KA, Hughes DA, Stocker SL, Vrijens B, Aronson JK, Wright DFB. A framework for understanding sources of bias in medication adherence research. Br J Clin Pharmacol. 2023;89(11):3444–3453. doi:10.1111/bcp.15863 PubMed DOI

Dalli LL, Kilkenny MF, Arnet I, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022;88(10):4427–4442. doi:10.1111/bcp.15391 PubMed DOI PMC

Pinho S, Cruz M, Ferreira F, Ramalho A, Sampaio R. Improving medication adherence in hypertensive patients: a scoping review. Prev Med. 2021;146:106467. doi:10.1016/j.ypmed.2021.106467 PubMed DOI

Granata N, Traversoni S, Kardas P, et al. Methodological features of quantitative studies on medication adherence in older patients with chronic morbidity: a systematic review. Patient Educ Couns. 2020;103(10):2132–2141. doi:10.1016/j.pec.2020.04.006 PubMed DOI

Memoli V, Ekanmian G, Lunghi C, Bouhnik AD, Lauzier S, Guénette L. What methods are used to study the association between medication adherence trajectories, estimated with the group-based trajectory modeling (GBTM) method, and health-related outcomes?-a protocol for a systematic review. Syst Rev. 2022;11(1):102. doi:10.1186/s13643-022-01971-y PubMed DOI PMC

Inotai A, Ágh T, Maris R, et al. Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treat Rev. 2021;100:102264. doi:10.1016/j.ctrv.2021.102264 PubMed DOI

Arnet I, Kooij MJ, Messerli M, Hersberger KE, Heerdink ER, Bouvy M. Proposal of standardization to assess adherence with medication records: methodology matters. Ann Pharmacother. 2016;50(5):360–368. doi:10.1177/1060028016634106 PubMed DOI